))
Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review
Manage episode 414543050 series 3381434
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
CME credits: 0.50
Valid until: 24-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-indolent-systemic-mastocytosis-a-multidisciplinary-case-review/18089/
New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.=
…
continue reading
Valid until: 24-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-indolent-systemic-mastocytosis-a-multidisciplinary-case-review/18089/
New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.=
680 episoade
Distribuie
